These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 32024944)

  • 1. CYP2C9 and VKORC1 genotyping for the quality of long-standing warfarin treatment in Russian patients.
    Panchenko E; Kropacheva E; Dobrovolsky A; Titaeva E; Zemlyanskaya O; Trofimov D; Galkina I; Lifshits G; Vereina N; Sinitsin S; Vorobyeva N; Grehova L; Zateyshchikov D; Zotova I; Vavilova T; Sirotkina O; Grontkovskaya A
    Pharmacogenomics J; 2020 Oct; 20(5):687-694. PubMed ID: 32024944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative performance of pharmacogenetics-based warfarin dosing algorithms derived from Caucasian, Asian, and mixed races in Thai population.
    Chumnumwat S; Yi K; Lucksiri A; Nosoongnoen W; Chindavijak B; Chulavatnatol S; Sarapakdi A; Nathisuwan S
    Cardiovasc Ther; 2018 Apr; 36(2):. PubMed ID: 29243335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of gene polymorphims on the warfarin treatment at initial stage.
    Liu J; Jiang HH; Wu DK; Zhou YX; Ye HM; Li X; Luo ZY; Guo Z; Zhang YL; Wang YC; Zhang W; Zhou HH; Wang LS
    Pharmacogenomics J; 2017 Jan; 17(1):47-52. PubMed ID: 26644206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Warfarin dose requirements with different genotypes of CYP2C9 and VKORC1 for patients with atrial fibrillation and valve replacement.
    Chen W; Wu L; Liu X; Shen Y; Liang Y; Zhu J; Tan H; Yang Y; Liu Q; Wang M; Liu L; Wang X
    Int J Clin Pharmacol Ther; 2017 Feb; 55(2):126-132. PubMed ID: 27117036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Genotype-Guided Warfarin Dosing in the Chinese Population: A Meta-analysis of Randomized Controlled Trials.
    Wang F; Guo J; Zhang A
    J Cardiovasc Pharmacol; 2019 Mar; 73(3):127-135. PubMed ID: 30688796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacogenetics of Warfarin in a Diverse Patient Population.
    Mak M; Lam C; Pineda SJ; Lou M; Xu LY; Meeks C; Lin C; Stone R; Rodgers K; Mitani G
    J Cardiovasc Pharmacol Ther; 2019 Nov; 24(6):521-533. PubMed ID: 31064211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of CYP2C9-VKORC1 interaction on warfarin stable dosage and its predictive algorithm.
    Li X; Liu R; Yan H; Tang J; Yin JY; Mao XY; Yang F; Luo ZY; Tan SL; He H; Chen XP; Liu ZQ; Li Z; Zhou HH; Zhang W
    J Clin Pharmacol; 2015 Mar; 55(3):251-7. PubMed ID: 25187307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of CYP2C9 and VKORC1 genetic variations on warfarin dose requirements in Indian patients.
    Natarajan S; Ponde CK; Rajani RM; Jijina F; Gursahani R; Dhairyawan PP; Ashavaid TF
    Pharmacol Rep; 2013; 65(5):1375-82. PubMed ID: 24399734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of UDP-Glucuronosyltransferase Polymorphisms on Stable Warfarin Doses in Patients with Mechanical Cardiac Valves.
    An SH; Chang BC; Lee KE; Gwak HS
    Cardiovasc Ther; 2015 Dec; 33(6):324-8. PubMed ID: 26223945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genotype-guided therapy improves initial acenocoumarol dosing. Results from a prospective randomised study.
    Cerezo-Manchado JJ; Roldán V; Corral J; Rosafalco M; Antón AI; Padilla J; Vicente V; González-Conejero R
    Thromb Haemost; 2016 Jan; 115(1):117-25. PubMed ID: 26538428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic and Non-Genetic Factors Affecting the Quality of Anticoagulation Control and Vascular Events in Atrial Fibrillation.
    Park YK; Lee MJ; Kim JH; Lee JS; Park RW; Kim GM; Chung CS; Lee KH; Kim JS; Lee SY; Bang OY
    J Stroke Cerebrovasc Dis; 2017 Jun; 26(6):1383-1390. PubMed ID: 28412319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A network meta-analysis of CYP2C9, CYP2C9 with VKORC1 and CYP2C9 with VKORC1 and CYP4F2 genotype-based warfarin dosing strategies compared to traditional.
    Sridharan K; Sivaramakrishnan G
    J Clin Pharm Ther; 2021 Jun; 46(3):640-648. PubMed ID: 33346393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation of pharmacogenetic algorithms and warfarin dosing table in Egyptian patients.
    Bazan NS; Sabry NA; Rizk A; Mokhtar S; Badary O
    Int J Clin Pharm; 2012 Dec; 34(6):837-44. PubMed ID: 22851439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Accuracy assessment of pharmacogenetically predictive warfarin dosing algorithms in patients of an academic medical center anticoagulation clinic.
    Shaw PB; Donovan JL; Tran MT; Lemon SC; Burgwinkle P; Gore J
    J Thromb Thrombolysis; 2010 Aug; 30(2):220-5. PubMed ID: 20204461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of CYP2C9-Interacting Drugs on Warfarin Pharmacogenomics.
    Agrawal S; Heiss MS; Fenter RB; Abramova TV; Perera MA; Pacheco JA; Smith ME; Rasmussen-Torvik LJ; George AL
    Clin Transl Sci; 2020 Sep; 13(5):941-949. PubMed ID: 32270628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized trial of genotype-guided dosing of warfarin.
    Pirmohamed M; Burnside G; Eriksson N; Jorgensen AL; Toh CH; Nicholson T; Kesteven P; Christersson C; Wahlström B; Stafberg C; Zhang JE; Leathart JB; Kohnke H; Maitland-van der Zee AH; Williamson PR; Daly AK; Avery P; Kamali F; Wadelius M;
    N Engl J Med; 2013 Dec; 369(24):2294-303. PubMed ID: 24251363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients.
    Miao L; Yang J; Huang C; Shen Z
    Eur J Clin Pharmacol; 2007 Dec; 63(12):1135-41. PubMed ID: 17899045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetics and clinical response to warfarin and edoxaban in patients with venous thromboembolism.
    Vandell AG; Walker J; Brown KS; Zhang G; Lin M; Grosso MA; Mercuri MF
    Heart; 2017 Nov; 103(22):1800-1805. PubMed ID: 28689179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. VKORC1 and CYP2C9 genotypic data-based dose prediction alone does not accurately predict warfarin dose requirements in some Malaysian patients.
    Chua YA; Abdullah WZ; Yusof Z; Gan SH
    Turk J Med Sci; 2015; 45(4):913-8. PubMed ID: 26422867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Warfarin dose requirement in patients having severe thrombosis or thrombophilia.
    Helin TA; Joutsi-Korhonen L; Asmundela H; Niemi M; Orpana A; Lassila R
    Br J Clin Pharmacol; 2019 Aug; 85(8):1684-1691. PubMed ID: 30933373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.